Sign In
Prof Michal Baniyash

Prof. Michal Baniyash​

Research In​​​terests

Inflammation related complications in non-cancerous and cancerous diseases

Chronic inflammation arising in various non-cancerous and cancerous diseases leads to an abnormal immunity and exposes patients to a variety of complications. These include suppression of the immune system, tissue damage, cardiovascular diseases and initiation of malignancies. It is important to note that chronic inflammation is considered as the “secret killer” as it operates within our body with no signs until complications appear. It is similar to a volcano. In cases of volcano related concerns, seismographs are needed to sense the worsening of the situation before the volcano bursts! Similarly, immune biomarkers, which are the seismographs of the immune system functionality, are needed to sense the immune status of patients and accordingly, direct the physician to apply the suitable type of treatment to avoid complications and health deterioration. During the years we discovered a set of immune biomarkers that could sense the individual’s immune system functionality and developed the detection technology. With these tools in hand, we could fulfill the clinical needs for monitoring the immune status of patients suffering from noncancerous and cancerous chronic diseases. We clinically applied our new technology and proof the concept in clinical studies that with the technology we developed we could achieve the following:
  1. Evaluate of the host’s immune system function and distinguish between acute (beneficial response) and chronic (harmful response) inflammation
  2. Predict responses to immune-based therapies applied today in cancer patients (as shown for melanoma patients treated with ipilimumab) and direct the type of treatment – published in Clinical Cancer research
  3. Detect disease regression or progression and directing the physician of which type of chemotherapy to give to CRC patients and follow responses – published in Cancer Research
  4. Predict the appearance of complications before they are evident as shown in diabetic patients.
Monitoring such immune system biomarkers is expected to have a major clinical impact in addition to unraveling the entangled complexity underlying abnormal immunity that is evident during chronic inflammation. Thus, newly discovered biomarkers and those that are currently under investigation are projected to open a new era towards combating the silent damage induced by chronic inflammation.​​